Cyndeo Wealth Partners’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.55M Buy
59,790
+1,398
+2% +$75.9K 0.12% 168
2026
Q1
$3.66M Buy
58,392
+13,004
+29% +$1.04M 0.19% 126
2025
Q4
$4.33M Buy
45,388
+2,210
+5% +$217K 0.23% 106
2025
Q3
$4.22M Sell
43,178
-1,692
-4% -$175K 0.23% 105
2025
Q2
$4.82M Buy
44,870
+1,586
+4% +$160K 0.29% 96
2025
Q1
$4.37M Buy
43,284
+4,383
+11% +$441K 0.29% 100
2024
Q4
$3.47M Buy
38,901
+3,191
+9% +$281K 0.23% 110
2024
Q3
$2.99M Sell
35,710
-9,856
-22% -$777K 0.21% 128
2024
Q2
$3.51M Buy
45,566
+912
+2% +$66.8K 0.27% 107
2024
Q1
$3.06M Sell
44,654
-6,286
-12% -$404K 0.25% 113
2023
Q4
$2.94M Sell
50,940
-26,397
-34% -$1.41M 0.27% 107
2023
Q3
$4.08M Buy
77,337
+6,321
+9% +$332K 0.43% 76
2023
Q2
$3.84M Sell
71,016
-16,202
-19% -$846K 0.4% 82
2023
Q1
$4.36M Buy
87,218
+13,253
+18% +$625K 0.47% 63
2022
Q4
$3.42M Buy
+73,965
New +$3.2M 0.4% 85

Other funds holding BSX

Cyndeo Wealth Partners's BSX Position: Q2 2026 in Review

Cyndeo Wealth Partners increased its Boston Scientific (BSX) stake by 2.4% in Q2 2026, buying an estimated $75.9K and bringing the position to 59,790 shares worth $2.55M. The position accounts for 0.12% of the portfolio, ranked #168.

Cyndeo Wealth Partners first reported a position in BSX in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.82M in Q2 2025. 241 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

  • Cyndeo Wealth Partners held 59,790 shares of Boston Scientific worth $2.55M as of Q2 2026.
  • Cyndeo Wealth Partners bought 1,398 Boston Scientific shares in Q2 2026, an estimated $75.9K.
  • Boston Scientific made up 0.12% of Cyndeo Wealth Partners's portfolio in Q2 2026, its #168 holding.
  • Cyndeo Wealth Partners first reported a position in Boston Scientific in Q4 2022 and has held it in 15 quarters since.
  • Cyndeo Wealth Partners's Boston Scientific position peaked at $4.82M in Q2 2025.
  • 241 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Cyndeo Wealth Partners's 13F filing for Q2 2026, filed 21 Jul 2026.